Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
768results about "Transforming growth factor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
P-amidobenzylethers in drug delivery agents
InactiveUS20030130189A1Decrease in drug activityImprove stabilityTetrapeptide ingredientsTripeptide ingredientsEtherDiluent
Compounds of the formulas LAn-Z-X-WwD and BZ-X-WwD wherein: D is a drug moiety; L is a ligand; B is a blocking group; A is an optional acyl unit; Z is an amino acid or a peptide; X is an aminobenzyl ether self-immolative spacer group; W is an optional second self-immolative group; n is an integer of 0 or 1; and w is an integer of 0 or 1, and compositions of said compounds with pharmaceutically acceptable carrier, diluent and / or excipient, and methods of delivery the drug D via the compounds.
Owner:SEAGEN INC
Medical device and methods of use of glaucoma treatment
InactiveUS7094225B2Lower eye pressureThe process is simple and effectiveBiocideSenses disorderAqueous outflowSchlemm's canal
The invention relates generally medical devices and methods for the treatment of glaucoma in an animal eye and, more particularly, to medical devices and methods for treating tissue of the trabecular meshwork and / or Schlemm's canal of the eye to restore or rejuvenate a portion or all of the normal physiological function of directing aqueous outflow for maintaining a normal intraocular pressure in the eye.
Owner:GLAUKOS CORP
Administration of growth factors for the treatment of CNS disorders
ActiveUS20070254842A1Prevents and delay onsetReduce severityHeavy metal active ingredientsSenses disorderDiseaseNervous system
A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and / or dysfunction is described.
Owner:RGT UNIV OF CALIFORNIA
Compositions And Methods For Self-Renewal And Differentiation In Human Embryonic Stem Cells
ActiveUS20070281355A1Efficient productionEffectively lead to differentiationPeptide/protein ingredientsMetabolism disorderGerm layerFeeder Layer
The present invention provides compositions and methods for the production of differentiated mammalian cells. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a feeder layer or under feeder-free conditions in cell culture and further contacting the cells with an inhibitor of the PI3-kinase pathway for the generation of differentiated mammalian cells from pluripotent mammalian stem cells. Preferably, the differentiated cell is selected from the group consisting of a mesendodermal cell, a mesodermal cell, and an endodermal cell.
Owner:UNIV OF GEORGIA RES FOUND INC +1
Subdermal tissue remodeling using myostatin, methods and related systems
ActiveUS20090226424A1High activityReduce wrinklesCosmetic preparationsOrganic active ingredientsMedicineBiomedical engineering
Systems and methods of tissue remodeling or altering a surface of a skin of a patient are provided. A method includes increasing myostatin activity in a target tissue. Methods can include increasing myostatin activity in a target tissue in addition to various tissue remodeling techniques, including cryogenic cooling of target tissue for tissue remodeling.
Owner:PACIRA CRYOTECH INC
Compositions and methods for the treatment of disease
InactiveUS20040209805A1Efficient transferAvoid cross contaminationOrganic active ingredientsPeptide/protein ingredientsAdjuvantMedicine
The present invention relates to pharmaceutical compositions for the treatment and / or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and / or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.
Owner:MONASH UNIV +1
Avian follistatin product
InactiveUS20070275036A1Prevent muscle wastingAvoid wastingBiocidePeptide/protein ingredientsFowlAnimal science
Described herein are avian follistatin products, and methods for producing such products, in which such products are effective for a variety of conditions, including increasing muscle mass. Avian follistatin products described herein are packaged as dietary supplements or nutritional supplements are useful in muscle regeneration.
Owner:MYOS
Decellularized bone marrow extracellular matrix
ActiveUS20050013872A1Minimizes and avoids immune responsePeptide/protein ingredientsSkeletal disorderCell-Extracellular MatrixInsertion stent
The invention is directed to compositions comprising decellularized bone marrow extracellular matrix and uses thereof. Methods for repairing or regenerating defective, diseased, damaged or ischemic tissues or organs in a subject, preferably a human, using the decellularized bone marrow extracellular matrix of the invention are also provided. The invention is further directed to a medical device, preferably a stent or an artificial heart, and biocompatible materials, preferably a tissue regeneration scaffold, comprising decellularized bone marrow extracellular matrix for implantation into a subject.
Owner:BOSTON SCI SCIMED INC
SRAM bus architecture and interconnect to an FPGA
Owner:ACTEL CORP
SRAM bus architecture and interconnect to an FPGA
An SRAM bus architecture includes pass-through interconnect conductors. Each of the pass-through interconnect conductors is connected to routing channels of the general interconnect architecture of the FPGA through an element which includes a pass transistor connected in parallel with a tri-state buffer. The pass transistors and tri-state buffers are controlled by configuration SRAM bits. Some of the pass-through interconnect conductors are connected by programmable elements to the address, data and control signal lines of the SRAM blocks, while other pass through the SRAM blocks without being further connected to the SRAM bussing architecture.
Owner:MICROSEMI SOC
Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
ActiveUS8187878B2Efficient productionEffectively lead to differentiationPeptide/protein ingredientsMetabolism disorderGerm layerFeeder Layer
Owner:UNIV OF GEORGIA RES FOUND INC +1
Compositions and Methods for Targeted Immunomodulatory Antibodies and Fusion Proteins
ActiveUS20130039911A1Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antobodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antobodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immuno-suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By conteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
In-Situ Forming Porous Scaffold
A composition includes a viscous gel formed from a combination of a biodegradable polymer and a biocompatible solvent. The composition also includes a hydrophilic porogen, which may be incorporated in the viscous gel. The composition may form a porous scaffold in situ.
Owner:ALZA CORP
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ActiveUS8216997B2Increased formationImprove the level ofOrganic active ingredientsPeptide/protein ingredientsPrimatePhysiology
Owner:ACCELERON PHARMA INC
Fc Variants Having Decreased Affinity for FcyRIIc
Owner:XENCOR INC
Coatings on medical implants to guide soft tissue healing
ActiveUS20060246105A1Peptide/protein ingredientsBone-inducing factorBiomedical engineeringSoft tissue
Embodiments include coatings or surface treatments for medical instruments, devices, and / or implants that promote soft tissue healing. More particularly, embodiments relate to treating portions of instruments, devices, and implants where tissue healing is desired with tissue healing promoting treatments.
Owner:WARSAW ORTHOPEDIC INC
Conjugation methods
ActiveUS20110003969A1Reduce potential steric hindrancePeptide/protein ingredientsMammal material medical ingredientsBiochemistryAntibody
This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues
Owner:IMMUNOGEN INC
Fusion proteins for blood-brain barrier delivery
ActiveUS20070081992A1Avoid significant immunogenic reactionAvoid significant reactionSenses disorderNervous disorderMediated transportBlood–brain barrier
The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.
Owner:ARMAGEN TECH +1
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
ActiveUS8993524B2Function increaseOrganic active ingredientsPeptide/protein ingredientsTumor targetAntitumor immunity
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immune suppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β) and regulatory T cells and / or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS20100028331A1Easy to produceReduce expressionPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed Cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Compositions and methods of treating fibrotic disorders
The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.
Owner:AMGEN INC
Self-assembling peptide amphiphiles and related methods for growth factor delivery
ActiveUS20050209145A1Promote binding epitope recognizedModulate their bio-availabilityAntibacterial agentsNervous disorderEpitopeAmphiphile
Owner:NORTHWESTERN UNIV
Growth factor HTTER36
InactiveUS20050244867A1Good for weight lossReduce excessive appetiteNervous disorderPeptide/protein ingredientsDiseaseGDF3
Owner:HUMAN GENOME SCI INC
Methods for increasing thermogenic adipocytes
ActiveUS8178488B2High expressionIncreasing thermogenic adipocytesOrganic active ingredientsPeptide/protein ingredientsNODALDisease
In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Owner:ACCELERON PHARMA INC
Targeted TGFβ inhibitors
ActiveUS9676863B2Effective therapyNervous disorderPeptide/protein ingredientsAntigenAntigen Binding Fragment
This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
Owner:MERCK PATENT GMBH
Formulations and methods for delivery of growth factor analogs
Formulations, kits and methods for bone or cartilage repair, including treatment of osteogenic defects, including formulations of synthetic heparin-binding growth factor analogs, non-ionic polymers, gelling agents and calcium-containing agents.
Owner:BROOKHAVEN SCI ASSOCS +1
Method for treating cardiac remodeling following myocardial injury
InactiveUS20060019890A1Improve heart functionWorsen cardiac functionPeptide/protein ingredientsDepsipeptidesDiseaseHeart disorder
The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said method comprising the administration of a natriuretic peptide to a patient in need thereof.
Owner:SCIOS
Multiribbon nanocellulose as a matrix for wound healing
InactiveUS20070053960A1Improve adaptabilityControl thicknessOrganic active ingredientsBiocideFiberWound healing
The present invention includes compositions and methods for the integration of a non-allergenic nanocellulose into a wound bed. The composition may be formed into a wide variety of implants, e.g., a suture, a sheet, a compress, a bandage, a band, a prosthesis, a fiber, a woven fiber, a bead, a strip, a clasp, a prosthesis, a catheter, a screw, a bone plate, a pin, a bandage or combinations thereof.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Antagonists of activin-actriia and uses for increasing red blood cell levels
ActiveUS8895016B2Reduce expressionIncrease red blood cell and hemoglobin levelPeptide/protein ingredientsAntibody mimetics/scaffoldsPrimateRed blood cell
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and / or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Owner:ACCELERON PHARMA INC
Pharmaceutical compositions for the stimulation of stem cells
InactiveUS20120301538A1Improve abilitiesOrganic active ingredientsPowder deliveryVeterinary pharmaceuticalsExcipient
The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating-agents and at least one pharmaceutically acceptable excipient.
Owner:CARDIO3 BIOSCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com